港股晨报 港股回顾 点，跌幅随即扩大至 247 点，低见 23730 点，其后跌幅 一度收窄至仅 20 点，午后大盘走势偏软，尾盘沽压再 度扩大。截至收盘，恒指收报 23831 点，下跌 145 点或 0.61%；国指收报 9656 点，下跌 47 点或 0.49%，大市 成交进一步减至 827.99 亿。港股通录得净流入资金 4.84 亿，其中港股通(沪)净流入 2.83 亿，港股通(深)净 周一港股放量上涨，有色金属行业领涨。恒生指 数收涨 0.67%，报 26033.26 点；恒生科技指数上 涨 0.82%；恒生中国企业指数上涨 0.47%。市场成 交额 2008.84 亿港元，南向资金净买入 21.48 亿 港元。恒生指数成分股中 71 只上涨。其中舜宇光 学科技上涨 6.2%，紫金矿业上涨 5.3%，国际银 价、铜价大幅上涨，带动有色金属板块走强。 美股市场 1. 美股周一收跌，三大股指均结束此前连续五个交易日 的上涨趋势。道指跌 427.09 点，跌幅为 0.90%，报 47289.33 点；纳指跌 89.76 点，跌幅为 0.38%，报 23275.92 点；标普 500 指数跌 36.46 点 ...

锦欣生殖医疗集团有限公司是一家投资控股公司，主要提供试管受精（IVF）服务。该公司通过其子公 司主要提供辅助生殖服务、管理服务、流动手术中心设施服务、辅助医疗服务、妇产儿科医疗服务，以 及从事医疗消耗品及设备销售业务。该公司主要在中国及美国提供服务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-12-01 | 14.85 Z | 290.25万 | 0.20% | | 2025-11-28 | 14.82亿 | 435.70万 | 0.29% | | 2025-11-27 | 14.78亿 | 348.85万 | 0.24% | | 2025-11-26 | 14.74亿 | 629.85万 | 0.43% | | 2025-11-25 | 14.68亿 | 1007.25万 | 0.69% | 证券之星消息，12月1日南向资金增持290.25万股锦欣生殖（01951.HK）。近5个交易日中，获 ...

锦欣生殖(01951)发布公告，根据购回授权，本公司获准于香港联合交易所有限公司(联交所)购回最多 2.74亿股股份，占于股东周年大会日期已发行股份(不包括库存股份)总数的10%。本公司认为，股份目 前的交易价格并未反映其内在价值或本公司的实际业务前景。因此，本公司董事会(董事会)已议决利用 购回授权，以不时在公开市场上按不少于1亿港元的总价格购回股份(建议股份购回)。本公司认为，建 议股份购回将展现本公司对其自身业务发展前景充满信心，而本公司现有财务资源将足以支持实施建议 股份购回，同时维持稳健的财务状况。 ...

锦欣生殖(01951)发布公告，根据购回授权，本公司获准于香港联合交易所有限公司(联交所)购回最多 2.74亿股股份，占于股东周年大会日期已发行股份(不包括库存股份)总数的10%。本公司认为，股份目 前的交易价格并未反映其内在价值或本公司的实际业务前景。因此，本公司董事会(董事会)已议决利用 购回授权，以不时在公开市场上按不少于1亿港元的总价格购回股份(建议股份购回)。本公司认为，建 议股份购回将展现本公司对其自身业务发展前景充满信心，而本公司现有财务资源将足以支持实施建议 股份购回，同时维持稳健的财务状况。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 Jinxin Fertility Group Limited - 1 - 1951 * 自願公告 建議於市場上購回股份 本公告乃由錦欣生殖醫療集團有限公司*（「本公司」）自願刊發。 茲提述本公司日期為2025年6月26日的公告，內容有關（其中包括）本公司股東於本公司於 2025年6月26日舉行的股東週年大會（「股東週年大會」）授出的購回本公司股份（「股份」）的 一般授權（「購回授權」）。根據購回授權，本公司獲准於香港聯合交易所有限公司（「聯交 所」）購回最多274,470,604股股份，佔於股東週年大會日期已發行股份（不包括庫存股份） 總數的10%。 本公司認為，股份目前的交易價格並未反映其內在價值或本公司的實際業務前景。因 此，本公司董事會（「董事會」）已議決利用購回授權，以不時在公開市場上按不少於1億港 元的總價格購回股份（「建議股份購回」）。本公司認為，建議股份購回將展現本公司對其 自身業務發展前 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 錦欣生殖醫療集團有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊 ...

Group 1 - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 6.2985 million shares on November 26, 2025, marking a 0.43% change [1][2] - Over the past five trading days, there have been five days of net increases in holdings, totaling 20.795 million shares [1][2] - In the last 20 trading days, there were 13 days of net increases, amounting to 31.1263 million shares [1][2] Group 2 - As of now, southbound funds hold 1.474 billion shares of Jinxin Reproductive Medicine, representing 53.44% of the company's total issued ordinary shares [1][2] - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and sales of medical consumables and equipment, mainly in China and the United States [2]

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 611,000 shares on November 24, 2025, marking a consistent trend of net increases over recent trading days [1] - Over the past 5 trading days, there has been a cumulative net increase of 11.76 million shares, while in the last 20 trading days, the total net increase reached 12.71 million shares [1] - As of now, southbound funds hold 1.458 billion shares of Jinxin Reproductive Medicine, accounting for 52.84% of the company's total issued ordinary shares [1] Summary by Category Trading Activity - On November 24, 2025, total shares held reached 1.458 billion, with a change of 611,000 shares, reflecting a 0.04% increase [2] - On November 21, 2025, total shares held were 1.457 billion, with a change of 630,000 shares, also a 0.04% increase [2] - On November 20, 2025, total shares held were 1.456 billion, with a change of 3.183 million shares, indicating a 0.22% increase [2] - On November 19, 2025, total shares held were 1.453 billion, with a change of 3.168 million shares, also a 0.22% increase [2] - On November 18, 2025, total shares held were 1.450 billion, with a change of 4.170 million shares, reflecting a 0.29% increase [2] Company Overview - Jinxin Reproductive Medicine is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin Reproductive Medicine operates mainly in China and the United States [2]

Core Insights - Southbound funds increased their holdings in Jinxin Reproductive Medicine (01951.HK) by 3.168 million shares on November 19, 2025, marking a 0.22% increase in total shares held [1][2] - Over the past five trading days, there have been four days of net increases in holdings, totaling 6.8563 million shares [1] - In the last twenty trading days, there were ten days of net increases, amounting to 9.4968 million shares [1] - As of now, southbound funds hold 1.453 billion shares of Jinxin Reproductive Medicine, representing 52.69% of the company's total issued ordinary shares [1] Company Overview - Jinxin Reproductive Medicine Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [2] - The company offers a range of services through its subsidiaries, including assisted reproductive services, management services, mobile surgical center facilities, auxiliary medical services, and maternal and pediatric medical services [2] - Jinxin operates mainly in China and the United States, also engaging in the sale of medical consumables and equipment [2]

JINXIN FERTILITY GROUP LIMITED (a company incorporated in the Cayman Islands with limited liability) SHARE SCHEME PREAMBLE 1. DEFINITIONS 1.1 In this Scheme, the following expressions have the following meanings: Acknowledgement Form shall have the meaning as defined in Rule 6.5; Actual Selling Price means the actual price at which the Option Shares or Restricted Shares are sold (net of brokerage, stamp duty, Stock Exchange trading fee, SFC transaction levy and any other applicable costs) on vesting of an A ...